tiprankstipranks
Advertisement
Advertisement

PVLA Stock Latest News

Palvella Therapeutics price target lowered to $207 from $210 at Truist
The FlyPalvella Therapeutics price target lowered to $207 from $210 at Truist
10d ago
PVLA
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
PremiumThe Fly
Palvella Therapeutics price target raised to $232 from $227 at Canaccord
10d ago
PVLA
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
PremiumRatings
Palvella Therapeutics: Strong Cash Runway and High-Confidence QTORIN Rapamycin Outlook Underpin New Buy Rating
10d ago
PVLA
High-Risk Warning for Investors in Palvella Therapeutics Securities
PremiumCompany Announcements
High-Risk Warning for Investors in Palvella Therapeutics Securities
10d ago
PVLA
Palvella Therapeutics Charts Clear Path From Data To Launch
PremiumCompany Announcements
Palvella Therapeutics Charts Clear Path From Data To Launch
11d ago
PVLA
Palvella Therapeutics reports Q2 EPS ($1.52), consensus ($1.15)
PremiumThe FlyPalvella Therapeutics reports Q2 EPS ($1.52), consensus ($1.15)
11d ago
PVLA
Palvella details QTORIN progress and Nasdaq uplisting milestones
Premium
Company Announcements
Palvella details QTORIN progress and Nasdaq uplisting milestones
11d ago
8K
PVLA
Short Report: Bears book profits in Celcuity
Premium
The Fly
Short Report: Bears book profits in Celcuity
20d ago
ARRY
BOBS
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
PremiumTipRanks Newswire
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunity
24d ago
PTN
CRNX
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
PremiumRatings
Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
25d ago
PVLA
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
PremiumRatings
Palvella Pharmaceuticals: Buy Rating Reiterated as QTORIN Regulatory Path Stays Intact; Price Target Unchanged at $225
25d ago
PVLA
H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial
PremiumThe Fly
H.C. Wainwright says Palvella selloff ‘an overreaction’ to FDA’s BTD denial
25d ago
PVLA
Palvella Therapeutics selloff a buying opportunity, says BTIG
PremiumThe FlyPalvella Therapeutics selloff a buying opportunity, says BTIG
25d ago
PVLA
Palvella Therapeutics falls -13.6%
Premium
The Fly
Palvella Therapeutics falls -13.6%
26d ago
PVLA
Palvella Therapeutics falls -9.0%
Premium
The Fly
Palvella Therapeutics falls -9.0%
26d ago
PVLA
Ligand price target raised to $345 from $330 at Craig-Hallum
PremiumThe Fly
Ligand price target raised to $345 from $330 at Craig-Hallum
26d ago
SNY
LGND
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
PremiumCompany Announcements
Palvella Therapeutics Highlights Growth Plans and QTORIN Progress
1M ago
8K
PVLA
Palvella Therapeutics Adds Industry Veteran to Board
PremiumCompany Announcements
Palvella Therapeutics Adds Industry Veteran to Board
2M ago
8K
PVLA
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
PremiumThe Fly
Palvella Therapeutics appoints Savara CEO Matt Pauls to board
2M ago
PVLA
SVRA
Palvella submits first rolling new drug application to FDA for Qtorin
PremiumThe FlyPalvella submits first rolling new drug application to FDA for Qtorin
2M ago
PVLA
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
Premium
The Fly
FDA grants rolling review to Palvella Therapeutics Qtorin rapamycin
2M ago
PVLA
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
Premium
Company Announcements
Palvella Therapeutics Expands Equity Plan, Confirms Board Leadership
2M ago
8K
PVLA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >